

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

VOLUNTARY ANNOUNCEMENT

ADMISSION OF DRUGS OF THE GROUP TO THE NATIONAL MEDICAL INSURANCE DRUG CATALOGUE

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the information of the latest business development of the Group.

On 20 August 2019, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China promulgated the latest version of the “National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance” (《國家基本醫療保險、工傷保險和生育保險藥品目錄》) (the “**National Medical Insurance Drug Catalogue**”), being the charging standard of drug fees for basic medical insurance, work-related injury insurance and maternity insurance fund, which shall be officially implemented from 1 January 2020.

The board of directors of the Company is pleased to announce that, a total of 70 products of the Group have been admitted to the National Medical Insurance Drug Catalogue. A number of products, including Uremic Clearance Granule (尿毒清顆粒) and Gadopentetic Acid Dimeglumine Salt Injection (鈆噴酸葡胺注射液), remained on the National Medical Insurance Drug Catalogue. Iopamidol Injection (碘帕醇注射液) is a newly manufactured product of the Group and remained in Class A of the National Medical Insurance Drug Catalogue. In addition, one product of the Group has been elevated from Class B to Class A in the National Medical Insurance Drug Catalogue, and three products have been admitted to the National Medical Insurance Drug Catalogue for the first time.

Product name	Applicable Disease	Change in the National Medical Insurance Drug Catalogue
Iopamidol Injection (碘帕醇注射液)	Used as a contrast medium for computer tomography	Class A of the western medicine category
Vital Essence Nourishing and Lungs Clearing Plaster (養陰清肺膏)	Used for nourishing vital essence, moisturizing the body, clearing lungs and relieving sore throat.	Elevated from Class B to Class A in the Chinese medicine category

Product name	Applicable Disease	Change in the National Medical Insurance Drug Catalogue
Kidney Repair and Edema Alleviation Granules (益腎化濕顆粒)	Used for the treatment of chronic glomerulonephritis and reducing proteinuria	Admitted to Class B of the Chinese medicine category for the first time
Iron-dextrin Oral Solution (右旋糖酐鐵口服溶液)	Used for the treatment of iron-deficiency anemia caused by chronic blood loss, malnutrition and pregnancy and during child growth, etc.	Admitted to Class B of the western medicine category for the first time
Cetirizine Hydrochloride Oral Solution (鹽酸西替利嗪口服溶液)	Used for the treatment of allergic rhinitis, urticaria and itchy skin	Admitted to Class B of the western medicine category for the first time

The Company is of the view that the change of the above drugs in the National Medical Insurance Drug Catalogue will be conducive to the sales of such products in the long run.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 22 August 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.